Novan (NOVN) – General News
-
U.S. stocks were rising after deal for SVB eases worries about banks
-
Top 5 stocks to end the year, according to Artificial Intelligence
-
Novartis trims sales outlook after hit from COVID disruptions
-
Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources
-
AstraZeneca sticks to 2020 outlook, boosted by drug stockpiling
-
Drugmaker Sanofi expects further profit growth from narrowed focus
-
Blackstone raises three-quarters of targeted $4.6 billion life sciences fund
-
Novartis wins Medicaid approval for new sickle cell drug in key U.S. states
-
Sanofi shares rally on new margin goals, narrower drug focus
-
Blackstone to invest $400 million in gene therapy venture with Ferring
-
Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker
-
Biogen, Eisai revive plans for Alzheimer's drug, surprising market
-
Novartis blames former AveXis executives for Zolgensma data manipulation
-
Novartis halts distribution of its Zantac versions amid probe into impurities
-
Novartis CEO promises to speed data integrity disclosures
-
Novartis names Bulto as new head of U.S. drugs business
-
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
-
GSK raises 2019 earnings expectations after standout quarter for Shingrix
-
Novartis raises full-year targets, aims to settle U.S. lawsuit
-
Take Five: G7 - deep in the Woods?
-
Novartis appoints Susanne Schaffert to lead oncology business
-
Brewer AB InBev partners with Tilray to tap cannabis drink market
-
Takeda CEO confident of investor backing for $62 billion Shire deal
-
AstraZeneca will keep UK investment freeze if no Brexit clarity
-
Stada, buyout funds in race for Bristol-Myers' French business: sources
-
Novartis to cut 2,550 jobs in Switzerland, UK in profit push
-
Toxin at heart of drug recall shows holes in medical safety net
-
Express Scripts staking out million-dollar gene therapies
-
Novartis hints at 2018 outlook hike despite drug price freeze
-
Novartis disputes U.S. senators' report on Cohen contract
-
FDA names drugmakers potentially acting to delay cheap generics
-
Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
-
Trump assails high drug prices, avoids direct hit on industry
-
Drugmaker GSK rings in more change as CFO heads for exit in 2019
-
Too many cancer drugs? Crowded market gives investors pause
-
Express Scripts targets Amgen, Lilly migraine drugs in pricing shift
-
GSK pulls out of $20 billion race for Pfizer consumer assets
-
GSK advances in Pfizer consumer health auction as Reckitt quits
-
GlaxoSmithKline prescribes commercial reboot for pharma division
-
Novartis CEO Narasimhan remakes drugmaker's leadership as Wyss exits
-
Greek PM wants politicians investigated in alleged Novartis bribery case
-
Special Report: Scientists describe problems in Philip Morris e-cigarette experiments
-
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
-
Drug industry on tenterhooks as Maryland price-gouging law nears
-
FDA panel backs Novartis' pioneering new cancer gene therapy
-
Novartis CEO sees no need for big takeover
-
Novartis has assets to sell, investors wary of what it might buy
-
Pre-Open Movers 12/27: Document Sciences (DOCX) Soars On Buyout, SLM (SLM) Slammed On Offering
-
After-Hours Movers 12/26: Noven (NOVN) Up on FDA Tentative Approval, SLM Corp (SLM) Down On Equity Offering
-
04/07 StreetInsider.com Pre-Open Movers
Back to NOVN Stock Lookup
